u/cold_chromatogram_only

a lot of the confident posting here is extrapolation

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.

What is the source for that figure — the published paper or a summary of it?

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

inter-lab variance runs a point or two, plan your outrage accordingly

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Adding the free proxy — track a few lifts monthly.

Agreed — and same machine, same conditions, or the two scans are not comparable.

How many separate lots does your series cover?

That protein figure is grams per day, not grams per kilogram. Different claim entirely.

Agreed that thin testing here says something about the members, not about the material.

Nothing here is a training or nutrition prescription. Targets and programmes are matters for somebody who knows your history and your training background.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

not approved anywhere, which is the single most important fact in this board

ranked feeds mean the top comment is not the best answer

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Push back: strength dropping in a deficit is not the same as lean mass loss. Related, not identical.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

removals get explained publicly where the rule allows it

Asked GL Biochem which lines they keep in regional stock versus make to order and got a clear split. It changed what I ordered.

The injection-site soreness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

Agreed — and appetite is the leading indicator.

This reframing is the most useful thing on the board for anyone approaching this phase.

the wiki is editable by anybody with standing on the site

Split one vial between Medutest and PeptideMeter. The two numbers were within half a point of each other and I stopped worrying about which lab to trust.

I would not post that as a finding. It is a single result and the template asks you to say so.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

Two scans on the same machine 20 months apart. Lean mass held better than I expected and the lifts told the same story for free.

Stretching the interval, reducing the dose, or both?

comparing reta phase 2 to sema phase 3 is comparing different things

Correcting myself upthread: 16 months between scans, not the figure I gave.

Three scans over eighteen months, same machine, same conditions. Only the third one made the first two interpretable.

Have the lifts held, dropped, or moved around?

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Agreed that the top comment is not the best answer. The ranking optimises for early agreement.

Have the lifts held, dropped, or moved around?

identity before purity, every time, for anything unusual